Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2025-12-31 @ 8:01 PM
Study NCT ID:
NCT02319005
Status:
COMPLETED
Last Update Posted:
2018-07-18
First Post:
2014-12-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Sponsor:
Alnylam Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-12
Start Date Type:
None
Primary Completion Date:
2017-03-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-03-30
Completion Date Type:
ACTUAL
First Submit Date:
2014-12-12
First Submit QC Date:
None
Study First Post Date:
2014-12-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-03-27
Results First Submit QC Date:
None
Results First Post Date:
2018-07-18
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-06-22
Last Update Post Date:
2018-07-18
Last Update Post Date Type:
ACTUAL